The problem with drug research is that current incentives reward companies to focus on new (or sufficiently new to patent) medicines of little advantage and compete for market share at high prices, rather than to develop clinically superior medicines by focussing on social benefit vs costs. More publicly funded research into drugs with high social benefits would also help.